Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

VAN NUYS, Calif.–(BUSINESS WIRE)–The Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) Level II code for the IpsiHand™ Upper Extremity Rehabilitation System by Neurolutions, Inc. This significant decision marks the first time a brain-computer interface (BCI) controlled therapy has been recognized with the receipt of a HCPCS code, setting a new benchmark for thought-activated controlled devices.

E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.

The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits. Utilizing BCI technology, the IpsiHand enables stroke survivors to engage in thought-actuated therapy, connecting movement to the intent to move signals within the brain, helping rebuild neuronal pathways.

CMS’ decision also includes a final Medicare benefit category determination, classifying the IpsiHand as Durable Medical Equipment (DME). This classification highlights the IpsiHand’s durability and appropriateness for home use, further emphasizing its role in advancing patient care and recovery outcomes. Neurolutions CEO, Leo Petrossian, expressed enthusiasm over the CMS decision, stating:

“We thank CMS for their decision and commitment to improving outcomes for stroke survivors by establishing a new HCPCS code, and for their support throughout the entire application process. This important milestone is a testament to the innovative spirit at Neurolutions, and a significant shift toward enhancing access to advanced rehabilitation technologies for stroke survivors across the nation.”

This is a step forward to establishing coverage for upper extremity rehabilitation therapies, opening the door for advancements in therapeutic BCI to generate better outcomes for patients and potentially lower the cost of care. Neurolutions is proud to partner with CMS to advance the forefront of the rapidly-growing frontier of BCI enabled post-stroke neurorehabilitation.

About Neurolutions, Inc.

Neurolutions is a medical technology company dedicated to transforming the lives of patients suffering from neurological conditions. Our mission is to develop innovative solutions that address the unmet needs of patients while advancing the field of neurorehabilitation through cutting-edge research and development.

The IpsiHand System is a breakthrough therapeutic device that uses brain-computer interface technology to help chronic stroke patients with an impaired upper extremity regain movement. The IpsiHand device has been clinically validated and has received FDA clearance for use in the United States.

https://neurolutions.com

Contacts

Media

Andy Schultz, CCO

marketing@neurolutions.com